Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Recce Pharmaceuticals to benefit from $5 million in government funds for AMR Research Hub

The company is pioneering the development of a new class of synthetic antibiotics with broad-spectrum activity, designed to address the problem of antibiotic superbugs.

Recce Pharmaceuticals Ltd (ASX:RCE) has been successful with a grant application as one of five industrial partners in collaboration with 16 university and public health organisations to establish a National Anti-Microbial Resistant (AMR) Research Hub in Sydney.

The hub will focus on combating antimicrobial resistance with the Australian Research Council awarding almost $5 million to the cause.

Recce and other leading industry partner organisations will engage with Australia’s key researchers and wider stakeholders to address the urgent challenge of antimicrobial resistance.

Working “to make a global contribution”

Recce chairman John Prendergast said: “If the world is to address the increasing threat of antimicrobial resistance, it's vital that governments, industry and academic researchers work together.

“The funding for this valuable interdisciplinary collaboration will help maximise the value of our product pipeline and accelerate our efforts to identify and commercialise new antibiotics for patients and clinicians worldwide.”

Prendergast added: “Participation aligns with our goals of working to make a contribution to global health and we look forward with the hub committee as a key industry partner.”

Collaboration partners

The hub is a collaboration with the following organisations

Universities:

  • University of New South Wales
  • University of Queensland
  • Monash University
  • University of Technology Sydney
  • University of Melbourne

Industrial partners:

  • SpeeDx Pty Ltd
  • Cepheid
  • Recce Pharmaceuticals Ltd
  • Opal Biosciences Ltd
  • Boulos and Cooper Pharmaceuticals Ltd

Public Research organisations:

  • The Global Antibiotic Research & Development Partnership (GARDP)
  • The Foundation for Innovative New Diagnostics (FIND)
  • The Central and Eastern Sydney Primary Health Network
  • NPS MedicineWise

Other collaborating organisations: Murdoch Children's Research Institute, WHO Collaborating Centre for Sexually Transmitted Infections and Antimicrobial Resistance, Melbourne Sexual Health Clinic, Western Sydney Sexual Health Centre, Sydney Sexual Health Centre, PNG Institute of Medical Research and Thai Red Cross AIDS Research Centre.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK